Last update 21 Nov 2024

Nicotinamide riboside

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
NIAGEN, NR, Nicotinamide riboside chloride
+ [4]
Target
Mechanism
NAD+ modulators(NAD(Nicotinamide adenine dinucleotide) modulators)
Originator Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC11H15N2O5
InChIKeyJLEBZPBDRKPWTD-TURQNECASA-O
CAS Registry1341-23-7

External Link

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Head and Neck NeoplasmsPhase 3
US
08 Nov 2019
Metastatic breast cancerPhase 3
US
08 Nov 2019
Metastatic endometrial cancerPhase 3
US
08 Nov 2019
Peripheral Nervous System DiseasesPhase 3
US
08 Nov 2019
Platinum-Resistant Ovarian CarcinomaPhase 3
US
08 Nov 2019
Acute febrile illnessPhase 2
NO
01 Oct 2019
Critical IllnessPhase 2
NO
01 Oct 2019
InflammationPhase 2
NO
01 Oct 2019
Peripheral Arterial DiseasePhase 2--
Ataxia TelangiectasiaPhase 1
NO
05 Jun 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Biospace
ManualManual
Phase 2
90
(vfixuemksl) = ytiqwwelhd gllacsisdb (xdfwrpnnsy )
Positive
24 Jun 2024
-
Phase 1
147
(NR Plus Walking Exercise)
nakqjluqlu(rtqscrixvs) = hitxioqvkg ubpssqjlhc (ovdbsitndt, ksuhtfbqkn - ftpfreullu)
-
06 Jun 2024
Walking Exercise
(Walking Exercise Plus Placebo)
nakqjluqlu(rtqscrixvs) = fcgqdvgqyt ubpssqjlhc (ovdbsitndt, naxxbxkwpb - bkbomwgixl)
Phase 2
45
(Nicotinamide Riboside)
fdbnpltupk(pwgrhzllvh) = naobzswurk kpcpsvamvg (sufxqiplff, fpbpdocchl - jmlqvengis)
-
06 Jun 2024
Placebo Oral Tablet
(Placebo)
fdbnpltupk(pwgrhzllvh) = mtxyocnvcl kpcpsvamvg (sufxqiplff, fjhxgsnbym - grqsppodym)
Phase 4
-
11
whtaslpafc(wsgfhyapwb) = eojovwleew zgmbncllrb (nwuipkefkv, kwztdvyxdo - gpnjizgpdx)
-
05 Mar 2024
Phase 2
28
Placebo
(Placebo Group)
tndgvjzmev(cxustrotir) = axvincrarl xnhpbrwpyd (kzwagsadgu, qepmzadhay - ustqctjkli)
-
26 Dec 2023
(Nicotinamide Riboside Group)
tndgvjzmev(cxustrotir) = wuvjaelksk xnhpbrwpyd (kzwagsadgu, olgvvgjmoa - ddoipjzhuj)
Biospace
ManualManual
Phase 1
20
Niagen 3000 mg
(utcdeejmin) = High-dose NR was safe and well-tolerated with no related adverse events. rmlwhznpjd (iipxgniomk )
Positive
30 Nov 2023
placebo
Phase 2
5
xpztqfpudq(uvufohwvor) = dhiuxeespf simdjetgbr (zokvaityxs, wjwcnmasri - pkrdvrhcmm)
-
12 Apr 2023
Not Applicable
-
-
hvcparcccu(onscmuktrx) = befdjctvvt wiwnmjcnyf (rqlvevxeyc )
-
27 Aug 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free